Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Mid-range Performer

1699.2000 -14.50 (-0.85%)

NSE Sep 11, 2025 15:31 PM

54.87% Gain from 52W Low

Volume: 43,002

Eris Lifesciences Ltd.

29 Jan 2022

1699.20

-0.85%

Eris Lifesciences (BUY): Cardio-metabolic segment headwinds hamper growth

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

Industry-wide slowdown in cardiometabolic segment (59% revenue share for ERIS) affected Q3 growth

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings